Dechra® Pharmaceuticals PLC (LSE symbol DPH) Releases its 2017 Half-yearly Financial Report

-  Core North American Pharmaceuticals (NA Pharmaceuticals) Segment revenue growth of 10.2% at CER (31.7% at AER).

-  Sales growth across all product groups; Companion Animal Products (CAP), Food producing Animal Products (FAP), Equine and Diets.

-  Strong performance from recently acquired businesses, exceeding our expectations.

-  Underlying operating profit increased by 28.6% at CER (47.1% at AER).

-  Net cash inflow from underlying operating activities of £43.9 million with a cash conversion of 124.0%.  

Financial Summary 

   
                                                       Restated      
                                        Six months     Six months   Growth at   Growth at
                                        ended          ended        actual      constant 
                                        31.12.16       31.12.15     exchange    exchange
                                        GBPm           GBPm         rate        rate
                                                   
    Revenue                              172.6          110.7       55.9%       34.7%
   

    Underlying
    Gross profit                          92.2           63.5       45.2%      27.2%
    Gross profit %                       53.4%          57.4%
    Operating profit                      38.6            26.3       47.1%     28.6%
    EBITDA                                41.6           28.7       45.0%      27.7%
    Diluted EPS                         31.25p         21.99p       42.1%      24.5%
   
    Reported
    Gross profit                          88.2           62.5       41.2%      24.0%
    Gross profit %                       51.1%          56.4%
    Operating profit                      17.6           15.9       10.7%
    Diluted EPS                          13.65p        12.74p        7.1%

Outlook 

The Group continues to perform well with current trading meeting management expectations. Our core portfolio continues to grow, the enhanced product pipeline is delivering new products and good progress has been made on the rationalisation and integration of our recent acquisitions. The Board therefore remains confident in our strategy, our future prospects and our expectations for full year performance.

To read the 2017 Half Yearly Report in full please visit http://www.dechra.com

Or at http://www.londonstockexchange.com/exchange/prices-and-markets/stocks/exchange-insight/company-news.html?fourWayKey=GB0009633180GBGBXSTMM

Notes 

All growth rates for both underlying and reported financial results included in the Dechra report are at CER, unless otherwise stated. This shows the year on year growth rates as if exchange rates had remained the same as in the previous year. The Group presents a number of non-GAAP Alternative Performance Measures (APM's). This allows investors to understand better the underlying performance of the Group, by excluding amortisation of acquired intangibles and impairment (if any) of acquired intangibles, acquisition expenses, fair value of uplift of inventory acquired through business combinations, rationalisation costs, loss on extinguishment of debt, and fair value and other movements on deferred and contingent consideration. EBITDA is defined as underlying earnings before interest, tax, depreciation and amortisation.

SOURCE Dechra Pharmaceuticals PLC